Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report

Detalhes bibliográficos
Autor(a) principal: Carvalho,Clarissa Luiza Dalla Bernardina
Data de Publicação: 2014
Outros Autores: Ortigosa,Luciena Cegatto Martins
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000100154
Resumo: The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
id SBD-1_40dbe50fb8e79f7add2b107de12d957c
oai_identifier_str oai:scielo:S0365-05962014000100154
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Segmental vitiligo after infliximab use for rheumatoid arthritis - A case reportArthritis, rheumatoidTumor necrosis factor-alphaVitiligoThe tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.Sociedade Brasileira de Dermatologia2014-02-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000100154Anais Brasileiros de Dermatologia v.89 n.1 2014reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20142887info:eu-repo/semantics/openAccessCarvalho,Clarissa Luiza Dalla BernardinaOrtigosa,Luciena Cegatto Martinseng2014-03-07T00:00:00Zoai:scielo:S0365-05962014000100154Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2014-03-07T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
title Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
spellingShingle Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
Carvalho,Clarissa Luiza Dalla Bernardina
Arthritis, rheumatoid
Tumor necrosis factor-alpha
Vitiligo
title_short Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
title_full Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
title_fullStr Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
title_full_unstemmed Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
title_sort Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
author Carvalho,Clarissa Luiza Dalla Bernardina
author_facet Carvalho,Clarissa Luiza Dalla Bernardina
Ortigosa,Luciena Cegatto Martins
author_role author
author2 Ortigosa,Luciena Cegatto Martins
author2_role author
dc.contributor.author.fl_str_mv Carvalho,Clarissa Luiza Dalla Bernardina
Ortigosa,Luciena Cegatto Martins
dc.subject.por.fl_str_mv Arthritis, rheumatoid
Tumor necrosis factor-alpha
Vitiligo
topic Arthritis, rheumatoid
Tumor necrosis factor-alpha
Vitiligo
description The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
publishDate 2014
dc.date.none.fl_str_mv 2014-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000100154
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962014000100154
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/abd1806-4841.20142887
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.89 n.1 2014
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126419464355840

Registros relacionados